Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

CANCER IMMUNOTHERAPY

Prevention of CAR-T-cell dysfunction

Nature Biomedical Engineering volume 4, pages 16–17 (2020)Cite this article

Subjects

The overexpression of the transcription factor c-Jun improves chimeric-antigen-receptor T-cell functionality and enhances the killing of low-antigen-expressing liquid and solid cancers in mice.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: c-Jun overexpression prevents T-cell dysfunction.

References

  1. Long, A. H. et al. Nat. Med. 21, 581–590 (2015).

    Article  CAS  Google Scholar 

  2. Fraietta, J. A. et al. Nat. Med. 24, 563–571 (2018).

    Article  CAS  Google Scholar 

  3. Lynn, R. C. et al. Nature https://doi.org/10.1038/s41586-019-1805-z (2019).

    Article  CAS  Google Scholar 

  4. Man, K. et al. Immunity 47, 1129–1141 (2017).

    Article  CAS  Google Scholar 

  5. Quigley, M. et al. Nat. Med. 16, 1147–1151 (2010).

    Article  CAS  Google Scholar 

  6. Pauken, K. E. et al. Science 354, 1160–1165 (2016).

    Article  CAS  Google Scholar 

  7. Sen, D. R. et al. Science 354, 1165–1169 (2016).

    Article  CAS  Google Scholar 

  8. Paley, M. A. et al. Science 338, 1220–1225 (2012).

    Article  CAS  Google Scholar 

  9. Miller, B. C. et al. Nat. Immunol. 20, 326–336 (2019).

    Article  CAS  Google Scholar 

  10. Martinez, G. J. et al. Immunity 42, 265–278 (2015).

    Article  CAS  Google Scholar 

  11. Liu, X. et al. Nature 567, 525–529 (2019).

    Article  CAS  Google Scholar 

  12. Khan, O. et al. Nature 571, 211–218 (2019).

    Article  CAS  Google Scholar 

  13. Porter, D. L. et al. Sci. Transl. Med. 7, 303ra139 (2015).

    Article  Google Scholar 

  14. Walker, A. J. et al. Mol. Ther. 25, 2189–2201 (2017).

    Article  CAS  Google Scholar 

  15. Sadelain, M., Rivière, I. & Riddell, S. Nature 545, 423–431 (2017).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Immunology, Blavatnik Institute, Harvard Medical School, Boston, MA, USA

    Martin W. LaFleur, Brian C. Miller & Arlene H. Sharpe

  2. Evergrande Center for Immunological Diseases, Harvard Medical School and Brigham and Women’s Hospital, Boston, MA, USA

    Martin W. LaFleur, Brian C. Miller & Arlene H. Sharpe

  3. Broad Institute of Harvard and Massachusetts Institute of Technology, Cambridge, MA, USA

    Martin W. LaFleur, Brian C. Miller & Arlene H. Sharpe

  4. Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

    Brian C. Miller

Authors
  1. Martin W. LaFleur
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Brian C. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arlene H. Sharpe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Arlene H. Sharpe.

Ethics declarations

Competing interests

A.H.S. has patents on the PD-L1/PD-L2/PD-1 pathway and on tumour immunotherapy licensed by Roche, Genentech and Novartis (US patent nos. 7,432,059, 7,722,868, 8,652,465, 9,457,080, 9,683,048, 9,815,898, 9,845,356, 9,988,452, 10,202,454 and 10,370,446), consults for Novartis, serves on the scientific advisory boards for Surface Oncology, SQZ Biotech, Elstar Therapeutics, Elpiscience, Selecta and Monopteros, and has received research funding from Merck, Novartis, Roche, Ipsen, UCB and Quark Ventures. The remaining authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

LaFleur, M.W., Miller, B.C. & Sharpe, A.H. Prevention of CAR-T-cell dysfunction. Nat Biomed Eng 4, 16–17 (2020). https://doi.org/10.1038/s41551-019-0512-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41551-019-0512-2

Search

Advanced search

Quick links

Nature Briefing: Cancer

Sign up for the Nature Briefing: Cancer newsletter — what matters in cancer research, free to your inbox weekly.

Get what matters in cancer research, free to your inbox weekly. Sign up for Nature Briefing: Cancer